@agathemouheb.bsky.social
PhD Student | MSB | Biostatistician
💡 Key findings:
📌 40% of ULT prescriptions were inappropriate based on kidney function.
📌 70% of these inappropriate prescriptions were not reassessed over 5 years.
📌 No significant association between ULT and slower CKD progression.
📢 Urate-Lowering Therapy and Chronic Kidney Disease, Journal of #Nephrology
👥 Using data from the French #CKD-REIN cohort
🚩 Our study highlights the lack of reassessment of #ULT in patient with #CKD. ULT was not associated with a slowing of CKD progression.
🖱️ Reed more: doi.org/0.1007/s4062...
📌 Our findings emphasize the importance of reassessing anticholinergic prescriptions in CKD patients to mitigate cognitive risks.
🖱️ Interested in the full study? Explore it here: doi.org/10.1111/jgs....
🔍 Our study highlights the frequent prescription of anticholinergic drugs in patients with chronic kidney disease (CKD) and their potential link to cognitive impairment.
📊 Graph: Therapeutic classes of anticholinergic drugs most commonly prescribed in the CKD-REIN cohort
@solenemlaville.bsky.social
04.12.2024 17:34 — 👍 0 🔁 0 💬 0 📌 0📊 Findings highlight the frequent use of anticholinergic drugs in CKD and their potential impact on cognition.
#CKD #Nephrology #Pharmacology #CKDREINcohort #AnticholinergicBurden #CognitiveImpairment
🔍We explored the link between anticholinergic drug burden and cognitive impairment in patients with chronic kidney disease (CKD).
👥 Using data from the French CKD-REIN cohort, which includes 3,033 patients under nephrology care (non-dialyzed, non-transplanted).
Excited to share our latest publication in JAGS!
📌 Our study emphasizes the importance of careful prescribing of anticholinergic drugs for patients with CKD.
🖱️Curious to learn more? Access the full study here: doi.org/10.1111/jgs....
